אוגמנטין תרחיף 250 מג5 מל
glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - אבקה להכנת תרחיף - amoxicillin as trihydrate 50 mg/ml; clavulanic acid as potassium salt 12.5 mg/ml - ampicillin and enzyme inhibitor - ampicillin and enzyme inhibitor - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.
אוגמנטין 250 מג טבליות
glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - טבליות מצופות פילם - amoxicillin as trihydrate 250 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused also by beta-lactamase producing organisms witch are susceptible to augmentin and are resistant to other beta-lactam antibiotics.
אוגמנטין 500 מג טבליות
glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - טבליות מצופות פילם - amoxicillin as trihydrate 500 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.
מאקליבן 250 מג5 מל
novartis israel ltd - amoxicillin as trihydrate; clavulanic acid as potassium - אבקה להכנת תרחיף - clavulanic acid as potassium 62.5 mg / 5 ml; amoxicillin as trihydrate 250 mg / 5 ml - combinations of penicillins, incl. beta-lactamase inhibitors - for the treatment of lower respiratory tract infections, otitis media infections , sinusitis, acute pharyngitis, skin and soft tissues infection, and urinary tract infections, caused also by beta-lactamase producing organisms which are susceptible to amoxiclav-teva and are resistant to other beta-lactam antibiotics.
מאקליבן 500 מג
novartis israel ltd - amoxicillin as trihydrate; clavulanic acid as potassium - טבליה - amoxicillin as trihydrate 500 mg; clavulanic acid as potassium 125 mg - combinations of penicillins, incl. beta-lactamase inhibitors - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis, acute pharyngitis, skin and soft tissues infection, and urinary tract infections, caused also by beta-lactamase producing organisms which are susceptible to amoxiclav-teva and are resistant to other beta-lactam antibiotics.
מאקליבן 400 מג 5 מל
novartis israel ltd - amoxicillin as trihydrate; clavulanic acid as potassium - אבקה להכנת תרחיף - amoxicillin as trihydrate 400 mg / 5 ml; clavulanic acid as potassium 57 mg / 5 ml - amoxicillin - amoxicillin - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused by beta-lactamase producing organisms which are susceptible to amoxycillin + potassium clavulanate and are resistant to other beta-lactam antibiotics.
קלוונטין 250
vitamed pharmaceutical industries ltd - amoxicillin as trihydrate; clavulanic acid as potassium - תרחיף - clavulanic acid as potassium 62.5 mg / 5 ml; amoxicillin as trihydrate 250 mg / 5 ml - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - lower respiratory infections, otitis media, sinusitis, acute pharyngitis, urinary tract infections, skin and soft tissue infections caused by beta-lactamase producing organisms susceptible to amoxycillin and clavulanic acid.
אוגמנטין תרחיף 125 מ"ג/5 מ"ל
glaxo smith kline (israel) ltd - amoxicillin as trihydrate 125 mg / 5 ml; clavulanic acid as potassium 31.25 mg / 5 ml - suspension - ampicillin and enzyme inhibitor - fot the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused also by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.
טימנטין 3.2 ג'
glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.
טימנטין 3.2 ג'
glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin as disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.